By Idris Umar, Zaria A major clinical trial of the cancer drug Niraparib has been launched in Nigeria to evaluate its safety, to...
By Idris Umar, Zaria
A major clinical trial of the cancer drug Niraparib has been launched in Nigeria to evaluate its safety, tolerability, and effectiveness as a maintenance therapy for women with advanced ovarian cancer.
The study, the first of its kind in Africa, aims to generate reliable data on the drug's performance among African populations and address the long-standing gap in cancer research caused by the underrepresentation of Africans in clinical trials.
Experts described the initiative as a significant milestone for cancer research, women's health, and the advancement of modern cancer treatment in Nigeria and across the African continent.
Speaking at the launch ceremony, the Chief Medical Director of Ahmadu Bello University Teaching Hospital (ABUTH), Professor Ahmadu Imdagas, said the research would provide immense benefits for Nigerians and other Africans living with ovarian cancer.
He disclosed that 70 women would be enrolled in the clinical trial, with ABUTH recruiting 22 participants during the first phase of the study.
Professor Imdagas noted that Niraparib is an expensive medication, costing approximately ₦11 million per course of treatment. He explained that conducting the trial in Nigeria would provide an opportunity to generate evidence that could support the development of treatment strategies better suited to African populations if the study proves successful.
He added that the initiative represents a source of pride for both ABUTH and Nigeria's health research community.
Also speaking at the event, Professor Matthew Schlumbrecht of the University of Miami described the introduction of the project in Nigeria as a major achievement.
He expressed confidence that the study would be successfully conducted and would yield valuable outcomes for patients while contributing to global cancer research.
In her remarks, one of the project leaders, Dr. A'isha Mustafa, expressed delight over the commencement of the trial, saying it would help improve the quality of life of women living with ovarian cancer in Nigeria and other African countries.
Delivering one of the keynote presentations, Professor Adekunle Oguntayo spoke on the prevalence of ovarian cancer and the current treatment landscape in Nigeria. His presentation was well received by participants.
Professor Schlumbrecht also presented an overview of the study, highlighting its rationale, objectives, and the expected long-term impact on women's health.
In his closing remarks, Barrister Buhari Zailani thanked the distinguished guests, researchers, and participants for attending the landmark event.
Experts believe the Niraparib clinical trial will mark a new chapter in cancer research in Nigeria by expanding opportunities for the development of innovative treatment approaches tailored to the needs of African patients.
The initiative forms part of broader efforts to strengthen scientific research, promote evidence-based healthcare, and improve cancer treatment outcomes across Africa.
No comments